WEBINAR: HDX-MS: a powerful tool for biopharmaceutical characterisation

Donstiennes, Belgium

Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):
a powerful tool for biopharmaceutical characterisation

 

Webinar banner Arnaud DELOBEL

 

Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) is a powerful technique for the advanced structural characterisation of proteins and the study of protein-protein interactions.This technique has been used for several decades, mostly in academic labs. Thanks to advances in automation, liquid chromatography and mass spectrometry technologies, this technique can now be used to get reproducible and reliable results in characterisation studies of biotherapeutics. It is complementary to other structural biology techniques such as NMR and X-ray cristallography. Its main advantage is to work in nearly physiological conditions and to require relatively limited amounts of sample.

The applications of HDX-MS for biopharmaceuticals characterisation are numerous, but this webinar addressed two main applications:

  • comparability studies to study structural differences between two batches of a product or a biosimilar and its innovator, or to evaluate structural modifications during stability studies

  • epitope mapping studies to determine the region of the antigen that is in interaction with a monoclonal antibody.

After a detailed description of the technique and its applications, case studies were presented.

 

Webinar HDX MS Arnaud Delobel Quality Assistance
Access this 45 minutes webinar to learn how HDX-MS can be applied throughout the development of your product to get structural information that can hardly be obtained with other techniques.

 

KEY LEARNING OBJECTIVES

Access this 45 minutes webinar to learn how HDX-MS can be applied throughout the development of your product to get structural information that can hardly be obtained with other techniques. After a detailed description of the technique and its applications, case studies were presented in the context of comparability and epitope mapping studies.

WHO WILL BENEFIT ?

  • Analysts

  • Scientists

  • Project leaders

  • Managers

  • Directors

in the biopharmaceutical industry, involved in:

  • advanced structural characterisation of biotherapeutics, 

  • comparability and biosimilarity studies, 

  • epitope mapping studies

EXPERTISE & CAPACITY

We provide a complete dedicated service:

  • A management team who can help you define the technical solution that best suits your needs

  • In accordance with GxP quality standards, as required by the study

  • Specialised, highly skilled scientists at the bench